IMI PLC (LON:IMI) Neutral Rating Reaffirmed by Analysts at Citigroup; With GBX 1260.00 Target; Epizyme (EPZM) Shorts Down By 1.25%

Epizyme Inc (NASDAQ:EPZM) had a decrease of 1.25% in short interest. EPZM’s SI was 5.17M shares in March as released by FINRA. Its down 1.25% from 5.24M shares previously. With 460,800 avg volume, 11 days are for Epizyme Inc (NASDAQ:EPZM)’s short sellers to cover EPZM’s short positions. The SI to Epizyme Inc’s float is 10.66%. The stock increased 2.84% or $0.5 during the last trading session, reaching $18.1. About 402,825 shares traded. Epizyme, Inc. (NASDAQ:EPZM) has risen 91.85% since March 12, 2017 and is uptrending. It has outperformed by 75.15% the S&P500.

They currently have a GBX 1260.00 target price on IMI PLC (LON:IMI). Citigroup’s target would suggest a potential upside of 11.01% from the company’s last stock price. This was shown in analysts report on Monday, 12 March.

Since September 18, 2017, it had 1 buy, and 3 insider sales for $1.35 million activity. Ho Peter Tai-Ching sold $246,591 worth of Epizyme, Inc. (NASDAQ:EPZM) on Tuesday, October 24. The insider Ros Matthew sold $1.20M. On Monday, September 18 MOTT DAVID M bought $3.05M worth of Epizyme, Inc. (NASDAQ:EPZM) or 200,000 shares.

Investors sentiment decreased to 1.21 in Q3 2017. Its down 0.25, from 1.46 in 2017Q2. It dived, as 15 investors sold Epizyme, Inc. shares while 22 reduced holdings. 13 funds opened positions while 41 raised stakes. 58.04 million shares or 22.28% more from 47.46 million shares in 2017Q2 were reported. Wells Fargo & Mn reported 36,473 shares. Citadel Advisors Limited Liability Company reported 437,849 shares. Pacad Invest Ltd holds 0.02% or 4,000 shares in its portfolio. Fmr Ltd Liability Corporation holds 10.17 million shares. Rhenman Ptnrs Asset Management, a Sweden-based fund reported 236,293 shares. Hbk Investments L P invested 0% in Epizyme, Inc. (NASDAQ:EPZM). Point72 Asset Mngmt Limited Partnership accumulated 923,400 shares or 0.08% of the stock. Moreover, Renaissance Techs Lc has 0.01% invested in Epizyme, Inc. (NASDAQ:EPZM) for 230,388 shares. Bain Capital Pub Equity Mngmt Ltd Liability Company holds 0.22% or 180,574 shares. Palo Alto Invsts Ltd Liability Corp owns 6.40 million shares. Nationwide Fund Advsr holds 0% of its portfolio in Epizyme, Inc. (NASDAQ:EPZM) for 43,274 shares. Bancshares Of New York Mellon Corporation accumulated 202,178 shares. 6.46M are held by Nea Co Limited Liability Company. Goldman Sachs Group reported 0% in Epizyme, Inc. (NASDAQ:EPZM). Northern Trust holds 0% or 516,940 shares in its portfolio.

Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops novel epigenetic therapies for patients with cancer and other diseases in the United States. The company has market cap of $1.25 billion. The Company’s product candidates include tazemetostat, an inhibitor of the EZH2 HMT, which is in five-arm Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma ; Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II and Ib clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial for elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function, as well as Phase II clinical trial in adult patients with ovarian cancer. It currently has negative earnings. The firm is also developing additional programs, such as pinometostat, an intravenously administered small molecule inhibitor of DOT1L for the treatment of acute leukemias; and PRMT5 inhibitor that is in Phase I clinical trial for patients with solid tumors and NHL.

Among 13 analysts covering Epizyme (NASDAQ:EPZM), 12 have Buy rating, 0 Sell and 1 Hold. Therefore 92% are positive. Epizyme had 31 analyst reports since August 6, 2015 according to SRatingsIntel. The rating was maintained by Oppenheimer with “Buy” on Wednesday, June 14. On Thursday, June 15 the stock rating was maintained by Leerink Swann with “Buy”. The stock has “Buy” rating by Jefferies on Wednesday, January 24. The rating was initiated by Citigroup on Tuesday, April 5 with “Buy”. H.C. Wainwright upgraded Epizyme, Inc. (NASDAQ:EPZM) on Monday, March 14 to “Buy” rating. H.C. Wainwright maintained it with “Buy” rating and $2500 target in Thursday, June 15 report. Roth Capital initiated it with “Buy” rating and $24.0 target in Thursday, February 1 report. RBC Capital Markets maintained Epizyme, Inc. (NASDAQ:EPZM) on Monday, September 28 with “Outperform” rating. Zacks downgraded the shares of EPZM in report on Tuesday, August 25 to “Buy” rating. Oppenheimer maintained the shares of EPZM in report on Tuesday, August 1 with “Buy” rating.

Among 23 analysts covering IMI PLC (LON:IMI), 8 have Buy rating, 1 Sell and 14 Hold. Therefore 35% are positive. IMI PLC has GBX 1500 highest and GBX 700 lowest target. GBX 1199.48’s average target is 5.87% above currents GBX 1133 stock price. IMI PLC had 199 analyst reports since July 27, 2015 according to SRatingsIntel. The rating was maintained by Morgan Stanley with “Overwt/In-Line” on Wednesday, October 7. On Tuesday, February 23 the stock rating was maintained by Deutsche Bank with “Hold”. Nomura maintained IMI plc (LON:IMI) rating on Tuesday, December 15. Nomura has “Buy” rating and GBX 972 target. Credit Suisse maintained the shares of IMI in report on Friday, October 28 with “Neutral” rating. The stock has “Neutral” rating by Citigroup on Tuesday, December 1. Credit Suisse maintained IMI plc (LON:IMI) rating on Friday, October 30. Credit Suisse has “Neutral” rating and GBX 980 target. The stock of IMI plc (LON:IMI) has “Overweight” rating given on Friday, November 11 by Barclays Capital. The rating was maintained by HSBC with “Hold” on Tuesday, August 16. The stock of IMI plc (LON:IMI) has “Neutral” rating given on Tuesday, August 4 by Credit Suisse. HSBC maintained the shares of IMI in report on Wednesday, February 3 with “Buy” rating.

Investors sentiment increased to 1.38 in 2017 Q3. Its up 0.82, from 0.56 in 2017Q2. It increased, as 4 investors sold IMI plc shares while 5 reduced holdings. 4 funds opened positions while 1 raised stakes. 18.61 million shares or 1.03% less from 18.81 million shares in 2017Q2 were reported. Ingalls And Snyder Lc accumulated 10,000 shares. Guggenheim Capital Lc, Illinois-based fund reported 10,779 shares. Blackrock reported 70,313 shares. Thompson Siegel And Walmsley Llc invested 0% of its portfolio in IMI plc (LON:IMI). Spark Mgmt Ltd Company owns 57,600 shares for 0% of their portfolio. Rbf Cap reported 0.01% in IMI plc (LON:IMI). Renaissance Techs holds 0% in IMI plc (LON:IMI) or 851,600 shares. Morgan Stanley has invested 0% of its portfolio in IMI plc (LON:IMI). Price T Rowe Associates Md reported 629,110 shares. Symmetry Peak Limited Liability accumulated 1.02 million shares. Raging Mgmt Limited owns 14.73 million shares or 2.33% of their US portfolio. Royal Commercial Bank Of Canada invested 0% of its portfolio in IMI plc (LON:IMI). Bridgeway Capital Mngmt holds 0% or 247,600 shares in its portfolio. Geode Limited Liability Com has 0% invested in IMI plc (LON:IMI). Vanguard Grp Incorporated holds 0% or 512,816 shares.

IMI plc designs, manufactures, and services engineered products that control the precise movement of fluids worldwide. The company has market cap of 3.05 billion GBP. The companyÂ’s IMI Critical Engineering division provides critical flow control solutions for vital energy and process industries. It has a 18.98 P/E ratio. This division offers anti-surge valve and actuator systems to liquefied natural gas compression facilities; integrated flow control systems for critical applications in fluid catalytic cracking; valves into the ethylene and polypropylene production processes, as well as delayed coking; and turbine by-pass valves for critical applications in conventional and nuclear power plants.